Historical bmy News Stories
Bristol Myers Squibb's Stock Declines Amidst Industry Developments
BMY stock dips 1.8% amid biopharmaceutical industry shifts.
BMY Eyes Breakout: Solid Q1, M&A Pressure Rises Up
Bristol‑Myers Squibb reported a steady but mixed Q1, while sector M&A activity and patent expiries are increasing strategic urgency. Technical momentum — with shares approaching a 52‑week high — plus institutional coverage position BMY at a potential inflection point driven by upcoming pipeline catalysts and dealmaking pressure.
BMY Boost: Sotyktu FDA Win Spurs PsA Revenue Gain!
Bristol‑Myers Squibb’s FDA approval of Sotyktu for psoriatic arthritis on March 6, 2026, provides a validated commercial growth lever for BMY in the S&P 500. The approval is supported by strong POETYK Phase 3 data; investors should weigh near‑term uplift against legacy revenue erosion and upcoming pipeline readouts.
BMY Boost: Collaborations, Guidance Drive Rally Q1
Bristol-Myers Squibb (BMY) strengthened its clinical and financial position this week with expanded ALS collaboration milestone payments, new lung cancer data co-developed with BioNTech, and upbeat 2026 guidance that lifted shares. Key near-term catalysts include a late-year Phase 3 readout for RYZ101 and ongoing partnership activity that aims to accelerate oncology development.
BMY Boost: Sotyktu FDA Win and Immuno Deal RptNow!
Bristol‑Myers Squibb (BMY) scored a concrete regulatory win with FDA approval of Sotyktu for psoriatic arthritis and signaled continued pipeline expansion via a sizable tumor‑activated immunotherapy pact. These developments offer tangible portfolio diversification amid renewed sector M&A valuation benchmarks.
BMY Outlook Brightens After Q4 Beat, M&A Signals Up
Bristol-Myers Squibb (BMY) strengthened after a Q4 2025 earnings beat, raised 2026 guidance and increasing institutional ownership. Sector M&A chatter — notably Merck’s reported interest in Revolution Medicines — may lift valuation benchmarks for BMY’s oncology assets.
BMY: Opdivo FDA Vote Apr 8, Q4 Beats Spark Rally!!
Bristol Myers Squibb (BMY) rallied after a stronger-than-expected Q4 and upbeat 2026 guidance, but the stock recently pulled back ahead of a pivotal April 8 PDUFA decision for Opdivo in Hodgkin lymphoma. Key metrics and near-term regulatory catalysts make BMY a stock to watch.
BMY Hits Headwinds: India Ruling, Orbital Deal EPS
Bristol‑Myers Squibb (BMY) faced a mixed week: a legal setback in India that clears the way for a biosimilar challenger to nivolumab, a $1.5B acquisition of Orbital Therapeutics, and a solid Q4 beat with raised 2026 guidance. These concrete events are driving near‑term volatility while reshaping revenue and pipeline dynamics.
BMY Q4 Beat; Cobenfy Delay Lifts Shares, Guidance!
Bristol‑Myers Squibb topped Q4 expectations with $12.5B revenue and raised 2026 guidance, while a delayed Phase III readout for Cobenfy surprisingly supported shares as management moves to shore up enrollment. The results and forward outlook drove above‑average volume and a notable stock uptick.